Trial Outcomes & Findings for Patient-Centered Heart Failure Trial (NCT NCT00461513)

NCT ID: NCT00461513

Last Updated: 2018-07-12

Results Overview

The primary outcome was average change in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score. This is reported for each group (Intervention and Usual Care). The average for each group and standard deviation are reported. A positive score change represents an improvement in overall patient health status for the group of patients with congestive heart failure. A negative score change represents a worsening in overall patient health status for the group of patients with congestive heart failure.

Recruitment status

COMPLETED

Target enrollment

384 participants

Primary outcome timeframe

12 months

Results posted on

2018-07-12

Participant Flow

Participant milestones

Participant milestones
Measure
Intervention
The PCDM intervention included evaluation of CHF care by the collaborative care (CC) team with treatment recommendations based on current ACC/AHA clinical practice guidelines, telemonitoring, and screening and treatment for comorbid depression. The CC team at each site included a primary care provider, cardiologist and psychiatrist, as well as nurse and pharmacist. For each intervention patient, there was initial assessment of care following the enrollment visit. Each intervention patient was re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients had daily telemonitoring, and their care was reviewed if the telemonitoring data suggested clinical deterioration.
Usual Care
Patients randomized to the usual care arm continued to receive care at the discretion of their regular VA providers (for a given patient, this could include cardiology specialty care in addition to PCP care, participation in site-specific CHF programs such as CHF patient education classes, etc.), in direct continuity with the care they were receiving prior to enrollment. Patients in the usual care group were given information sheets that outlined self-care for CHF, and provided with a scale if needed at the enrollment visit. Patients in the usual care group had the same amount of interaction with the study team as the intervention patients (i.e. complete questionnaires at the same frequency; have the same study visits). PCPs of usual care patients were notified of the results of all screening studies (patient survey results, lab tests).
Overall Study
STARTED
187
197
Overall Study
COMPLETED
165
172
Overall Study
NOT COMPLETED
22
25

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Patient-Centered Heart Failure Trial

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Intervention Group
n=187 Participants
Baseline characteristics of patients who enrolled and were randomized to the Intervention Group, and who had at least one follow-up Kansas City Cardiomyopathy Questionnaire (at 3, 6, or 12 months). Therefore the total number completed in the Intervention Arm was 165, but we had at least one follow-up Kansas City Cardiomyopathy Questionnaire result on 187 patients.
Usual Care Group
n=197 Participants
Baseline characteristics of patients who enrolled and were randomized to the Usual Care Group, and who had at least one follow-up Kansas City Cardiomyopathy Questionnaire (at 3, 6, or 12 months).Therefore the total number completed in the Usual Care Arm was 172, but we had at least one follow-up Kansas City Cardiomyopathy Questionnaire result on 197 patients.
Total
n=384 Participants
Total of all reporting groups
Age, Continuous
67.3 years
STANDARD_DEVIATION 9.6 • n=5 Participants
67.9 years
STANDARD_DEVIATION 10.6 • n=7 Participants
67.6 years
STANDARD_DEVIATION 10.0 • n=5 Participants
Sex: Female, Male
Female
9 Participants
n=5 Participants
4 Participants
n=7 Participants
13 Participants
n=5 Participants
Sex: Female, Male
Male
178 Participants
n=5 Participants
193 Participants
n=7 Participants
371 Participants
n=5 Participants
Race/Ethnicity, Customized
White race
149 participants
n=5 Participants
165 participants
n=7 Participants
314 participants
n=5 Participants
Race/Ethnicity, Customized
Non-white race
38 participants
n=5 Participants
32 participants
n=7 Participants
70 participants
n=5 Participants
Kansas City Cardiomyopathy Overall Score
37.9 units on a scale
STANDARD_DEVIATION 13.3 • n=5 Participants
36.9 units on a scale
STANDARD_DEVIATION 14.6 • n=7 Participants
37.4 units on a scale
STANDARD_DEVIATION 13.8 • n=5 Participants

PRIMARY outcome

Timeframe: 12 months

The primary outcome was average change in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score. This is reported for each group (Intervention and Usual Care). The average for each group and standard deviation are reported. A positive score change represents an improvement in overall patient health status for the group of patients with congestive heart failure. A negative score change represents a worsening in overall patient health status for the group of patients with congestive heart failure.

Outcome measures

Outcome measures
Measure
Intervention
n=187 Participants
Usual Care
n=197 Participants
Change in Chronic Heart Failure Health Status Between Baseline and 12 Months.
13.5 units on a scale
Standard Deviation 16.7
13.5 units on a scale
Standard Deviation 18.6

SECONDARY outcome

Timeframe: 12 months

Mortality at 1 year

Outcome measures

Outcome measures
Measure
Intervention
n=187 Participants
Usual Care
n=197 Participants
Mortality at 1 Year
8 Participants
19 Participants

SECONDARY outcome

Timeframe: 12 months

Hospitalization at 1 year

Outcome measures

Outcome measures
Measure
Intervention
n=187 Participants
Usual Care
n=197 Participants
Hospitalization at 1 Year
55 Participants
59 Participants

Adverse Events

Intervention

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Usual Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Meg Plomondon

Veterans Health Administration

Phone: 303-370-75770

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place